[Cardiac adverse events from non-cardiac drugs].
Prevention of adverse events of non-cardiological medicinal products is essentially based on the knowledge that they exist and quantification of the risk to which the patient is exposed, both in terms of frequency and potential severity.
Monsuez
J J
JJ
Service de Médecine Interne, Hôpital Paul Brousse, 12, avenue Paul Vaillant Couturier, F 94804 Villejuif.
Charniot
J C
JC
D016907:Adverse Drug Reaction Reporting Systems; D018927:Anti-Asthmatic Agents / Q000009:adverse effects; D000890:Anti-Infective Agents / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000009:adverse effects; D016903:Drug Monitoring / Q000379:methods; D005765:Gastrointestinal Agents / Q000009:adverse effects; D006331:Heart Diseases / Q000139:chemically induced* / Q000517:prevention & control; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans
D018927:Anti-Asthmatic Agents; D000890:Anti-Infective Agents; D000970:Antineoplastic Agents; D014150:Antipsychotic Agents; D005765:Gastrointestinal Agents